<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617899</url>
  </required_header>
  <id_info>
    <org_study_id>CardioNavi</org_study_id>
    <nct_id>NCT04617899</nct_id>
  </id_info>
  <brief_title>The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance Criteria</brief_title>
  <acronym>SUPERIOR</acronym>
  <official_title>The Study to Evaluate the Performance and Safety of the Novasight Hybrid System Using Objective Performance Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioNavi MedTech (Wuhan) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Jingruitianhe Medical Science and Technology Development Co,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioNavi MedTech (Wuhan) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, multicenter, single-arm study aims to evaluate the safety, operability and&#xD;
      practicability of the novel hybrid intravascular imaging system/catheter during the&#xD;
      percutaneous transluminal coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clear image length measured by Core lab</measure>
    <time_frame>During the procedure</time_frame>
    <description>The clear image length is transformed from the clear image frame, and the ratio of the clear image can be calculated by Clear image length / Full image length * 100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catheter-related major adverse events</measure>
    <time_frame>Periprocedure</time_frame>
    <description>Cardiac death, myocardial infarction, blood-limited dissection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clear stent length measured by Core lab</measure>
    <time_frame>During the procedure</time_frame>
    <description>Clear stent length is defined as the total stent length visualized within the clear image length.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>During the procedure</time_frame>
    <description>Successfully deliver the catheter to the target lesion and withdrawal without fracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>During the procedure</time_frame>
    <description>Successfully imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image quality evaluated by operator</measure>
    <time_frame>During the procedure</time_frame>
    <description>Objective and subjective assessment of image quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>System reliability evaluated by operator</measure>
    <time_frame>During the procedure</time_frame>
    <description>Objective and subjective assessment of system reliability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter operability evaluated by operator</measure>
    <time_frame>During the procedure</time_frame>
    <description>Objective and subjective assessment of catheter operability.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Novasight IVUS/OCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A coronary segment with stent will be imaged by the Novasight IVUS/OCT catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Intravascular imaging</intervention_name>
    <description>Use of imaging catheter</description>
    <arm_group_label>Novasight IVUS/OCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be at least 18 years of age and less than 85 years of age.&#xD;
&#xD;
          2. Subject must be informed and sign a written consent&#xD;
&#xD;
          3. Subject must have evidence of myocardial ischemia, unstable angina or acute myocardial&#xD;
             infarction suitable for PCI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or cannot eliminate the possibility to be pregnant.&#xD;
&#xD;
          2. Estimated creatinine clearance &lt;30 ml/min/1.73 m2 using Cockcroft equation.&#xD;
&#xD;
          3. LVEF(Left ventricular ejection fraction) &lt; 35% by the most recent imaging test within&#xD;
             7 days prior to procedure.&#xD;
&#xD;
          4. Unstable ventricular arrhythmias.&#xD;
&#xD;
          5. High bleeding risk, active peptic ulcers or cerebrovascular accident or transient&#xD;
             ischemic attack within the past 6 months.&#xD;
&#xD;
          6. Known contraindication to anticoagulants and antiplatelets therapy.&#xD;
&#xD;
          7. Known hypersensitivity to aspirin, clopidogrel, heparin, iodinated contrast,&#xD;
             ticagrelor, bivalirudin, metal materials in stent.&#xD;
&#xD;
          8. Any intervention for not target vessel within 48 hours after the study procedure.&#xD;
&#xD;
          9. Any conditions that, in the investigator's opinion, could limit the subject's ability&#xD;
             to participate in the clinical investigation.&#xD;
&#xD;
        Angiographic exclusion criteria:&#xD;
&#xD;
          1. The reference diameter of target vessel is less than 2.5 mm.&#xD;
&#xD;
          2. The target lesion involves myocardial bridge.&#xD;
&#xD;
          3. The target lesion is in the left main coronary artery or the damage is observed in the&#xD;
             ostium.&#xD;
&#xD;
          4. Severe calcification in the target vessel.&#xD;
&#xD;
          5. Severe tortuosity in the target vessel.&#xD;
&#xD;
          6. Multiple contiguous stent implantation in the target vessel.&#xD;
&#xD;
          7. Subject has coronary artery spasm.&#xD;
&#xD;
          8. In-stent restenosis.&#xD;
&#xD;
          9. Any study lesion characteristic that, in the investigator's opinion, is not available&#xD;
             for intravascular imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Muyan Zou</last_name>
    <phone>0086-15564579827</phone>
    <email>zoumuyan@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Chaoyang District</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Zeng, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Fengtai District</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Haidian District</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Jing, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Yundai Chen, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Haidian District</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yida Tang, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravascular imaging</keyword>
  <keyword>Intravascular ultrasound</keyword>
  <keyword>Optical coherence tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>According to the policy of the Human Genetic Resource Administration of China, the data is limited and it could not be shared currently.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

